Travaux scientifiques

Prof. Dr. Saadettin Kılıçkap

479 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study

    Future Oncology, 2022

    DOI 10.2217/fon-2022-0083 PMID 35734870 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  2. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

    Journal of Cancer Research and Clinical Oncology, 2022

    DOI 10.1007/s00432-022-04087-x PMID 35689097 11 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  3. Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group

    Medicine, 2022

    DOI 10.1097/md.0000000000032368 PMID 36550824 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  4. Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study

    Cancer, 2022

    DOI 10.1002/cncr.34477 PMID 36308296 18 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  5. External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

    Clinical Genitourinary Cancer, 2022

    DOI 10.1016/j.clgc.2022.07.006 PMID 35970759 6 citations (Europe PMC) Source : OpenAlex

  6. The Percentage of ALK-Positive Cells and the Efficacy of First-Line Alectinib in Advanced Non-small Cell Lung Cancer Is it a novel factor for stratification? (Turkish Oncology Group Study)

    Research Square, 2022

    DOI 10.21203/rs.3.rs-1583429/v1 Texte intégral en libre accèsSource : ORCID

  7. Lung Cancer in Turkey

    Journal of Thoracic Oncology, 2022

    DOI 10.1016/j.jtho.2022.06.001 PMID 36192076 12 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  8. Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease

    Journal of Clinical Medicine, 2022

    DOI 10.3390/jcm11175171 PMID 36079101 8 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  9. Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study

    European Journal of Clinical Pharmacology, 2022

    DOI 10.1007/s00228-022-03403-1 PMID 36266366 5 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  10. Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study

    Research Square, 2022

    DOI 10.21203/rs.3.rs-1840215/v2 Texte intégral en libre accèsSource : ORCID

  11. Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study

    Breast, 2022

    DOI 10.1016/j.breast.2022.09.009 PMID 36208540 16 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  12. Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy

    Eurasian Journal of Medicine and Oncology, 2022

    DOI 10.14744/ejmo.2022.78280 4 citations (OpenAlex) Texte intégral en libre accèsSource : ORCID

  13. Oncologists’ attitudes towards prophylaxis of cancer associated venous thromboembolism: A prospective, descriptive study

    Journal of Oncology Pharmacy Practice, 2022

    DOI 10.1177/10781552211035704 PMID 34559022 5 citations (Europe PMC) Source : ORCID

  14. Pazopanib-induced chylothorax in a patient with renal cell carcinoma

    Anti-Cancer Drugs, 2022

    DOI 10.1097/cad.0000000000001172 PMID 34387587 4 citations (Europe PMC) Source : ORCID

  15. Response to first-line chemotherapy regimen is associated with efficacy of ımmune checkpoint blockade therapies in patients with metastatic urothelial carcinoma

    International Journal of Clinical Oncology, 2022

    DOI 10.1007/s10147-021-02072-x PMID 34762201 5 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  16. Severe progressive dermatomyositis in a patient with metastatic ovarian cancer using bevacizumab

    Indian Journal of Pharmacology, 2022

    DOI 10.4103/ijp.ijp-11-22 Source : ORCID

  17. The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy

    Journal of Clinical Medicine, 2022

    DOI 10.3390/jcm11154523 PMID 35956139 28 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  18. The Association between the Pan‐Immune‐Inflammation Value and Cancer Prognosis: A Systematic Review and Meta‐Analysis

    Cancers, 2022

    DOI 10.3390/cancers14112675 PMID 35681656 171 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  19. The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors

    Cancer Biomarkers, 2022

    DOI 10.3233/cbm-210349 PMID 34958005 9 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  20. The benefit of treatment beyond progression with immune checkpoint inhibitors: A multi- center study

    Research Square, 2022

    DOI 10.21203/rs.3.rs-1867719/v1 Texte intégral en libre accèsSource : ORCID

  21. The burden of polypharmacy and drug–drug interactions in older cancer patients treated with immunotherapy

    Journal of Oncology Pharmacy Practice, 2022

    DOI 10.1177/10781552211012038 PMID 33878976 9 citations (Europe PMC) Source : ORCID

  22. The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond A Turkish Oncology Group Kidney Cancer Consortium (TKCC) study

    Research Square, 2022

    DOI 10.21203/rs.3.rs-1494936/v1 Texte intégral en libre accèsSource : ORCID

  23. The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study

    Journal of Cancer Research and Clinical Oncology, 2022

    DOI 10.1007/s00432-022-04055-5 PMID 35616728 22 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  24. The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors

    Scientific Reports, 2022

    DOI 10.1038/s41598-022-20056-3 PMID 36192500 15 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  25. Severe progressive dermatomyositis in a patient with metastatic ovarian cancer using bevacizumab

    Indian Journal of Pharmacology, 2022

    DOI 10.4103/ijp.ijp_11_22 PMID 36204814 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

  26. Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report

    Cureus, 2022

    DOI 10.7759/cureus.27828 PMID 36106272 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  27. 112P Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation

    Annals of Oncology, 2022

    DOI 10.1016/j.annonc.2022.02.139 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  28. CLO22-074: Patient-Reported Outcomes (PROs) in Patients (pts) With Advanced Non-Small Cell Lung Cancer (aNSCLC) With Programmed Cell Death-Ligand 1 (PD-L1) ≥50% Receiving Cemiplimab (CEMI) Monotherapy Versus Platinum-Doublet Chemotherapy (CHEMO): A Focus on the EMPOWER-Lung 1 Brain Metastases Subpopulation

    Journal of the National Comprehensive Cancer Network, 2022

    DOI 10.6004/jnccn.2021.7246 1 citation (OpenAlex) Source : OpenAlex

  29. LBA54 Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial

    Annals of Oncology, 2022

    DOI 10.1016/j.annonc.2022.08.056 10 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  30. Efficacy/safety of entrectinib in patients (pts) with ROS1-positive (ROS1+) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST).

    Journal of Clinical Oncology, 2022

    DOI 10.1200/jco.2022.40.17_suppl.lba9023 4 citations (OpenAlex) Source : OpenAlex

  31. EP08.01-024 Multicenter Real Life Clinical Outcomes of PDL-1 Tested Patients with Non Small Cell Lung Cancer (NSCLC) in Turkey

    Journal of Thoracic Oncology, 2022

    DOI 10.1016/j.jtho.2022.07.596 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  32. Long-term outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice.

    Journal of Clinical Oncology, 2022

    DOI 10.1200/jco.2022.40.6_suppl.474 1 citation (OpenAlex) Source : OpenAlex

  33. EE193 The Health Impact Projection Model of the PD-1/PD-L1 Inhibitor Class in Cancer Care in Turkey

    Value in Health, 2022

    DOI 10.1016/j.jval.2022.04.442 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  34. 582 Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Eastern cooperative oncology group (ECOG) performance status subgroups in EMPOWER-Lung 1

    Journal for ImmunoTherapy of Cancer, 2022

    DOI 10.1136/jitc-2022-sitc2022.0582 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  35. Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: A multicenter study.

    Journal of Clinical Oncology, 2022

    DOI 10.1200/jco.2022.40.4_suppl.130 Source : OpenAlex

  36. CLO22-050: Hospitalization and Supportive Care Medication (SCM) Utilization in Patients (pts) With Advanced Non-Small Cell Lung Cancer (aNSCLC) in EMPOWER-Lung 1

    Journal of the National Comprehensive Cancer Network, 2022

    DOI 10.6004/jnccn.2021.7238 Source : OpenAlex

  37. Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study

    Research Square, 2022

    DOI 10.21203/rs.3.rs-1840215/v1 Texte intégral en libre accèsSource : OpenAlex

  38. 773P Differences between hyperprogressive disease and progressive disease in patients receiving immunotherapy

    Annals of Oncology, 2022

    DOI 10.1016/j.annonc.2022.07.899 Texte intégral en libre accèsSource : OpenAlex

  39. 1612P Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy

    Annals of Oncology, 2022

    DOI 10.1016/j.annonc.2022.07.1705 Texte intégral en libre accèsSource : OpenAlex

  40. HPR12 Treatment Inequities Among Cancer Patients Due to Reimbursement: From the Perspective of 130 Medical Oncologists

    Value in Health, 2022

    DOI 10.1016/j.jval.2022.09.1144 Texte intégral en libre accèsSource : OpenAlex

  41. Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience

    Cancer Investigation, 2021

    DOI 10.1080/07357907.2021.1933011 PMID 34014777 10 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  42. Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group

    Journal of Gastrointestinal Cancer, 2021

    DOI 10.1007/s12029-021-00594-1 PMID 33538958 4 citations (Europe PMC) Source : OpenAlex

  43. Factors affecting survival in retroperitoneal sarcomas treated with upfront surgery: A real-world study by Turkish Oncology Group

    Van Yüzüncü Yıl University Academic Data Management System, 2021

    DOI 10.4999/uhod.215190 2 citations (OpenAlex) Source : OpenAlex

  44. Retrospective evaluation of malignant melanoma patients: A single-center experience

    Family practice and palliative care, 2021

    DOI 10.22391/fppc.717911 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  45. P84.03 GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients

    Journal of Thoracic Oncology, 2021

    DOI 10.1016/j.jtho.2021.01.1202 Texte intégral en libre accèsSource : OpenAlex

  46. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

    The Lancet, 2021

    DOI 10.1016/s0140-6736(21)00228-2 PMID 33581821 644 citations (Europe PMC) Source : OpenAlex

  47. Nivolumab in Metastatic Renal Cell Carcinoma: Results from the Turkish Oncology Group Kidney Cancer Consortium Database

    Future Oncology, 2021

    DOI 10.2217/fon-2021-0717 PMID 34726480 7 citations (Europe PMC) Source : OpenAlex

  48. Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis.

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.15_suppl.9085 9 citations (OpenAlex) Source : OpenAlex

  49. Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ≥ 50%: Results from EMPOWER-Lung 1 study.

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.15_suppl.9078 3 citations (OpenAlex) Source : OpenAlex

  50. Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.6_suppl.321 1 citation (OpenAlex) Source : OpenAlex